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Abstract
Objective In chronic fatigue syndrome (CFS), only a few
imaging and histopathological studies have previously as-
sessed either cardiac dimensions/function or myocardial
tissue, suggesting smaller left ventricular (LV) dimensions,
LV wall motion abnormalities and occasionally viral persis-
tence that may lead to cardiomyopathy. The present study
with cardiac magnetic resonance (CMR) imaging is the first
to use a contrast-enhanced approach to assess cardiac in-
volvement, including tissue characterisation of the LV wall.
Methods CMR measurements of 12 female CFS patients
were compared with data of 36 age-matched, healthy fe-
male controls. With cine imaging, LV volumes, ejection
fraction (EF), mass, and wall motion abnormalities were
assessed. T2-weighted images were analysed for increased
signal intensity, reflecting oedema (i. e. inflammation). In
addition, the presence of contrast enhancement, reflecting
fibrosis (i. e. myocardial damage), was analysed.
Results When comparing CFS patients and healthy con-
trols, LVEF (57.9 ± 4.3 % vs. 63.7 ± 3.7 %; p < 0.01), end-
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diastolic diameter (44 ± 3.7 mm vs. 49 ± 3.7 mm; p < 0.01),
as well as body surface area corrected LV end-diastolic vol-
ume (77.5 ± 6.2 ml/m2 vs. 86.0 ± 9.3 ml/m2; p < 0.01),
stroke volume (44.9 ± 4.5 ml/m2 vs. 54.9 ± 6.3 ml/m2; p <
0.001), and mass (39.8 ± 6.5 g/m2 vs. 49.6 ± 7.1 g/m2; p =
0.02) were significantly lower in patients. Wall motion ab-
normalities were observed in four patients and contrast en-
hancement (fibrosis) in three; none of the controls showed
wall motion abnormalities or contrast enhancement. None
of the patients or controls showed increased signal intensity
on the T2-weighted images.
Conclusion In patients with CFS, CMR demonstrated lower
LV dimensions and a mildly reduced LV function. The pres-
ence of myocardial fibrosis in some CFS patients suggests
that CMR assessment of cardiac involvement is warranted
as part of the scientific exploration, which may imply serial
non-invasive examinations.
Keywords Cardiovascular magnetic resonance · Chronic
fatigue syndrome · Contrast enhancement · Left ventricular
function · Myocardial damage
Introduction
Chronic fatigue syndrome (CFS) is relatively common with
an estimated worldwide prevalence of 0.4–1 % [1]. The
diagnosis of CFS relies on the presence of unexplained
persistent or relapsing chronic fatigue in combination with
a cluster of clinical symptoms [1–3]. Various potential
aetiologies have been discussed. Ongoing research sug-
gests that latent (chronic active) myocardial infections with
Epstein-Barr virus or human cytomegalovirus may trigger
CFS, and myocardial fibrosis has been described in this set-
ting [4–6]. In CFS, cardiac involvement has been reported
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with reduced left ventricular (LV) dimensions, decreased
left ventricular ejection fraction (LVEF), LV wall motion
abnormalities, and cardiomyopathies with virus persistence
in the myocardium [7–10].
Cardiac magnetic resonance (CMR) imaging may be
useful for the non-invasive assessment of cardiac involve-
ment in patients with CFS. This technique permits the ex-
amination of cardiac morphology and function, and even
tissue characterisation of the LV wall to identify oedema or
myocardial fibrosis – the consequences of myocardial in-
flammation [11]. Contrast-enhancement CMR imaging al-
lows the identification of myocardial fibrosis. T2-weighted
imaging, on the other hand, allows the visualisation of my-
ocardial oedema and may be useful for staging myocarditis
[12]. In the only other study with CMR imaging in the
setting of CFS, 12 patients and 10 matched controls were
assessed with cine and tagging imaging, but without the use
of the contrast enhancement technique (i. e. without tissue
characterisation) [7].
Therefore, in the present study with CMR imaging in pa-
tients with confirmed CFS, we used a combined approach
of cine, contrast-enhanced, and T2-weighted imaging to
assess LV tissue characteristics in addition to cardiac di-
mensions and function. Data from 12 patients with CFS
were then compared with data from an age- and gender-
matched group of 36 healthy controls, who were examined
with the same imaging protocol.
Methods
Study population
We studied 48 females with a combined CMR approach.
A consecutive series of 12 patients with CFS were recruited
from a specialised CFS centre, to be examined with CMR.
The diagnosis of CFS was based on the revised case def-
inition by Fukuda et al. [3] after ruling out other poten-
tial causal diseases. Measurements in the 12 CFS patients
were then compared with 36 age-matched, healthy female
volunteers without any comorbidities (control group), who
provided informed consent prior to CMR examination. The
study complied with the Declaration of Helsinki for inves-
tigation in human beings, and was performed after approval
and supervision of our institutional ethics committee.
CMR data acquisition
CMR examination was performed on a 1.5-T whole body
scanner (Achieva scan, Philips Medical Systems, Best, the
Netherlands) using commercially available cardiac CMR
software. For signal reception, a five-element cardiac syn-
ergy coil was used. Electrocardiogram triggering was done
with a vector electrocardiogram setup. Subjects were ex-
amined in the supine position. Morphological images in
the standard views were acquired by using fast field echo
cine images (slice thickness 8.0 mm; repetition time 3.4 ms;
echo time 1.7 ms; flip angle 60°; matrix 256 × 256).
Subsequently, a breath-hold, black-blood, T2-weighted
double-inversion recovery sequence with a fat-saturation
pulse was performed in 8–10 short-axis slices, with the
following parameters: repetition time 1800–2400 ms; echo
time 80 ms; matrix 256 × 256; field of view 32–40 cm;
slice thickness 12 mm; number of excitations 1. Myocardial
scar was assessed on contrast-enhanced multislice standard
views, obtained approximately 10 minutes after intravenous
bolus injection of 0.2 mmol gadolinium per kilogram body
weight (Shering AG, Berlin, Germany). A three-dimen-
sional Turbo Field Echo inversion recovery T1-weighted
sequence was used with the following parameters: repeti-
tion time 4.0 ms; echo time 1.3 ms; flip angle 15°; inver-
sion time individually optimised to null myocardial signal
(usually between 180–250 ms); matrix 157; slice thickness
10–12 mm).
CMR data analysis and definitions
CMR data were analysed on a workstation using dedicated
software for cardiac analysis (Philips MR workspace, Re-
lease 2.5.3.0 2007-12-03; Philips, the Netherlands). Left
ventricular end-diastolic (ml) and end-systolic volumes
(ml), stroke volume (ml), LVEF (%) cardiac output (l/min),
and end-diastolic wall mass (g) were calculated from con-
tiguous short-axis loops by segmentation of endocardial
and epicardial borders on each frame. Papillary muscles
were regarded as part of the ventricular cavity.
The left ventricular wall regions were divided into
17 segments according to a standardised myocardial seg-
mentation model [13]. Normal wall motion was assigned
a score of 0, mild hypokinesia 1, severe hypokinesia 2,
akinesia 3, and dyskinesia as 4. The wall motion score
index was calculated by dividing the sum of scores in each
segment by the total number of observed segments. T2-
weighted images were considered if abnormal increased
signal intensity was visually observed within the my-
ocardium.
The contrast-enhanced images were independently eval-
uated by three experienced observers, who were blinded
to patient/control characteristics and to the evaluations of
each other. Contrast enhancement was defined as a zone
of hyperenhancement on the late contrast-enhanced images
(in contrast with the dark-grey signal of the normal my-
ocardium). The studies were considered abnormal when at
least two independent observers described the same abnor-
malities with agreement in both the presence of contrast
enhancement and its location (same segment), reproducible
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Table 1 Baseline demographics of CFS patients and age-matched control group of normal, female subjects
Variables CFS patients Control group p value
Age (years) 36 ± 3 29 ± 8 0.11
Female patients n (%) 12 (100 %) 36 (100 %) NA
Body height (cm) 168 ± 6.6 171 ± 6.4 0.28
Body weight (kg) 60.3 ± 9.6 64.7 ± 8.8 0.16
BMI 21.3 ± 2.2 22.2 ± 2.5 0.24
BSA 1.7 ± 0.2 1.7 ± 0.3 0.78
HR (beats/min) 80 ± 16 70 ± 13 0.09
SBP (mm Hg) 133 ± 1 124 ± 17 0.18
DBP (mm Hg) 77 ± 8 75 ± 12 0.63
Data are expressed as mean ± standard deviation or frequencies and percentages
BMI body mass index, BSA body surface area, HR heart rate, SBP systolic blood pressure, DBP diastolic blood pressure, NA not applicable
Table 2 CMR findings in CFS patients and comparison with an age-matched control group of normal, female subjects
Variables CFS patients Control group Mean difference + 95 % CI p value
LVEDD (mm) 44 ± 3.7 49 ± 3.7 5 (2.68–7.66) <0.05
EDV (ml) 129.8 ± 16.0 148.9 ± 19.0 19.1 (6.75–31.47) <0.05
EDV/BSA (ml/m2) 77.5 ± 6.2 86.0 ± 9.3 8.4 (2.58–14.27) <0.05
LVESD (mm) 29.7 ± 4.1 30.5 ± 3.2 0.8 (–1.48–3.18) 0.47
ESV (ml) 54.7 ± 10.1 54.0 ± 9.2 0.7 (–6.99–5.71) 0.84
ESV/BSA (ml/m2) 32.6 ± 4.0 30.9 ± 4.8 1.7 ± 1.6 (–4.92–1.48) 0.29
IVS (mm) 7.9 ± 0.9 8.1 ± 1.1 0.3 (–0.44–0.97) 0.46
EDWM (g) 60.6 ± 10.6 86.6 ± 11.7 26.0 (18.30–33.70) <0.05
EDWM/BSA (g/m2) 39.8 ± 6.5 49.6 ± 7.1 9.9 (5.16–14.59) <0.05
SV (ml) 75.0 ± 8.9 96.2 ± 11.7 21.2 (13.68–28.73) <0.05
SV/BSA (ml/m2) 44.9 ± 4.5 54.9 ± 6.3 10.0 (6.07–14.03) <0.05
CO (l/min) 4.9 ± 1.3 6.6 ± 1.2 1.7 (0.77–2.56) <0.05
LVEF (%) 57.9 ± 4.3 63.7 ± 3.7 5.8 (3.19–8.41) <0.05
WMSI 0.02 ± 0.04 0.00 ± 0.00 0.02 (–0.04––0.01 0.054
T2 weighted oedema
(presence, n)
0 NA NA –
CE (presence, n) 3 0 – –
Data are expressed as mean ± standard deviation or frequencies and percentages
CI confidence interval, LVEDD left ventricular end-diastolic diameter, EDV end-diastolic volume, BSA body surface area, LVESD left ventricular
end-systolic diameter, ESV end-systolic volume, IVS interventricular septum, EDWM end-diastolic wall mass, SV stroke volume, SVI stroke
volume index, CO cardiac output, LVEF left ventricular ejection fraction, WMSI wall motion score index, CE contrast enhancement, NA not
applicable
in more than one contiguous slice and in more than one
projection.
Statistical analysis
Continuous variables had a normal distribution and were
expressed as mean ± standard error. Categorical data were
expressed as frequencies and percentages. To compare our
CMR findings in CFS patients, we used age- and gender-
matched controls. Student’s t-test and the Mann-Whitney U
test were used to compare continuous variables, and chi-
square test and Fisher’s exact test were used to compare




Twelve female CFS patients and 36 age- and gender-
matched controls were analysed in this study. The pa-
tients and controls were relatively young (36 ± 13 vs. 29 ±
8 years). All but one CFS patient had a history of infectious
mononucleosis disease with IgG antibodies to Epstein-Barr
virus or human cytomegalovirus capsid antigen; all of these
eleven patients had antibodies to Epstein-Barr virus nuclear
antigen. Demographics and baseline characteristics did not
differ between both groups (see also Table 1).
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Fig. 1 CMR findings in patient
with chronic fatigue syndrome.
Patient 1. a T2-weighted
CMR imaging short-axis
view; no presence of in-
creased signal intensity was
observed. b, c, d Contrast-en-
hanced-CMR imaging short-axis
view, four-chamber view and
two-chamber view; arrow
demonstrates midwall contrast
enhancement in the basal infer-
oseptal, septal and anteroseptal
segments
CMR results
The complete CMR examination protocol was followed in
all CFS patients and controls; image sequences of a high
quality could be obtained in all cases. CMR data of our CFS
population are presented in Table 2. In CFS patients, LVEF
(57.9 ± 4.3 %; p < 0.01), end-diastolic diameter (44 ± 3.7),
as well as body surface area corrected end-diastolic LV vol-
ume (77.5 ± 6.2 ml/m2; p < 0.01), LV stroke volume (44.9 ±
4.5 ml/m2; p < 0.001), and LV wall mass (39.8 ± 6.5 g/m2;
p = 0.02) were significantly lower than age- and gender-
matched controls. Mild wall motion abnormalities were
observed in four CFS patients in the basal and/or mid infer-
oseptal wall, leading to a wall motion score index of 0.02 ±
0.04; none of the controls showed wall motion abnormali-
ties. Myocardial damage (i. e. fibrosis), as indicated by the
presence of contrast enhancement, was observed in three
patients who showed such lesions in the basal inferoseptal,
septal, and anteroseptal midwall segments. An example is
presented in Fig. 1. No contrast enhancement was seen in
healthy controls. Only one patient showed both contrast
enhancement and wall motion abnormalities. Regional or
global oedema, as indicated by an increased signal inten-
sity on T2-weighted images, was not observed in any of the
patients.
Discussion
Data of cardiac magnetic resonance imaging
The present CMR study used a combined CMR approach
of cine, contrast enhancement, and T2-weighted imaging to
assess cardiac dimensions, function, and myocardial tissue
characteristics in patients with confirmed CFS and healthy
controls. Our data demonstrate a left ventricular size, mass,
and function that were lower than in age- and gender-
matched controls, although still within the normal range.
Theoretically, this difference could partially explain some
mild fatigue in these patients, but it may also be suggested
that the reduction in LV dimensions and function is the
result of reduced physical activity. In this respect, Take-
naka et al. found significantly reduced ventricular diastolic
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[14]. These findings are also in accordance with a previ-
ous echocardiographic study, which revealed a smaller LV
chamber with a lower cardiac output in CFS patients during
pharmacological stress testing [15].
Recently, Hollingsworth et al. investigated geometrical
and functional LV parameters with CMR, including strain
analysis, in 12 CFS patients and 10 healthy controls [7].
Although not all analyses gave evidence of myocardial dys-
function in CFS patients, residual torsion at 150 % of the
end-systolic time was greater in CFS patients than controls,
suggesting a delay in the release of torsion. In CFS pa-
tients, both residual torsion at 150 % of the end-systolic
time and torsion to endocardial strain ratio correlated nega-
tively with the end-diastolic volume index. These findings
may contribute to the understanding of cardiac functional
impairments in CFS patients [7].
In the present study, we also performed contrast-en-
hanced imaging in both CFS patients and a control group.
We found no increase in signal intensity (i. e. oedema)
on the T2-weighted CMR images, which demonstrates that
our patients did not suffer from an active state of viral my-
ocardial infection at the time of CMR. Midwall contrast
enhancement, a finding that has frequently been observed
in patients with histopathological evidence of chronic ac-
tive or borderline myocarditis [16], was found in three out
of 12 CFS patients. As demonstrated by Mahrholdt et al.
in patients with acute myocarditis, contrast enhancement
may not be detectable in approximately 25 % of patients
at an average follow-up of 4.5 months [17]. Therefore,
one may hypothesise that the initial myocardial involve-
ment in our CFS patient population might have been some-
what larger than observed in our CMR examination during
chronic state. The presence of a non-permissive, persistent
viral infection, in which only a very low level of complete
infectious virus is produced, could be a potential explana-
tion of isolated midwall contrast enhancement (so, in the
absence of oedema) [18] as observed in three of our CFS
patients.
Pattern and pathophysiology of myocardial damage
Previous myocarditis CMR studies demonstrated a rela-
tion between the type of virus and the pattern of myocar-
dial damage [17]. Accordingly, the distribution of con-
trast enhancement may help to distinguish between differ-
ent viral infections of the myocardium. In our CFS pa-
tients, contrast enhancement was exclusively observed in
the infero- and antero-septum, which fits well with my-
ocardial infections by Epstein-Barr virus [19], or human
cytomegalovirus; serum antibodies for at least one of these
viruses were identified in 11 of our CFS patients. Notably,
inferoseptal wall motion abnormalities were observed in
one patient with and three patients without contrast en-
hancement. In patients with myocarditis, the value and
interpretation of contrast enhancement can be difficult be-
cause of the heterogeneous scar distribution and the gen-
erally lower signal intensities. In addition, due to limited
voxel resolution, smaller myocardial scars may not be de-
tected. Another explanation for this discrepancy could be
the absence of contrast enhancement in the chronic state. To
the best of our knowledge, this study is the first to suggest
a septal predilection pattern of contrast enhancement and/or
wall motion abnormalities in CFS patients. In CFS patients,
myocardial fibrosis may lead to ventricular dysfunction, as
in patients with Chagas myocarditis, for instance, in whom
a relation between the amount of contrast enhancement and
late ventricular dysfunction has been described [20].
Clinical implications and consequences
In the present study, in patients with CFS, diagnosis was
based on the diagnostic criteria of Fukuda et al. [3]. Future
studies might also assess cardiac morphology and function
in patients with myalgic encephalomyelitis and its diagnos-
tic criteria [21]. Few data are available on prevalence and
extent of cardiac involvement in CFS patients. With our
combined CMR approach, we demonstrated in one exami-
nation (although in the normal range) lower size, mass, and
function of the left ventricle and structural abnormalities
of the myocardium, as previously assessed separately with
different techniques. Specific treatment of myocarditis re-
mains a challenge [6, 22]. A small, randomised, placebo-
controlled trial on the use of antiviral therapy for patients
with a Epstein-Barr virus subset of CFS found a clinical
improvement after six months [23]. Recently, it has been
suggested that Epstein-Barr virus can provoke ventricular
tachycardia by both acute and chronic myocardial inflam-
mation, emphasising the clinical importance of this viral in-
fection [19]. To test the hypothesis that Epstein-Barr and/or
human cytomegalovirus may lead to ventricular dysfunc-
tion, myocardial involvement, and CFS, further studies are
warranted that should include early and repeat examinations
with a combined CMR approach plus targeted myocardial
tissue biopsies. Such serial studies may answer the question
of whether some CFS patients develop a dilated cardiomy-
opathy with the inherent risk of an inferior clinical course
[6].
Limitations and technical considerations
We did not perform serial serological tests or myocardial
biopsies. It would have been ideal to correlate CMR find-
ings with targeted endomyocardial biopsies. However, this
would have involved an invasive procedure without a di-
rect therapeutic implication. In patients with myocarditis,
the value and interpretation of contrast enhancement can be
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difficult because of heterogeneous scar distribution and the
generally lower signal intensities [4, 24–26]. Although our
data are unique, findings in this small population of CFS
patients cannot answer the question whether the somewhat
lower cardiac function may contribute to the reduced exer-
cise capacity or may be a result of lower physical activity.
Further assessment of relationships between exercise ca-
pacity and CMR parameters in a larger patient population
is of interest and should be addressed by future studies.
Conclusion
In patients with chronic fatigue syndrome, CMR demon-
strated relatively lower dimensions and a mildly reduced
function of the left ventricle. The presence of myocardial
fibrosis in some CFS patients suggests that further assess-
ment of cardiac involvement may be warranted as part of
a further scientific exploration of the CFS disease. This
may imply serial non-invasive examinations with CMR.
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